Stockhub

Iovance Biotherapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 August 2022

  • curprev 07:1507:15, 23 August 2022 >Nick 1,180 bytes +1,180 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurre..."
Retrieved from "https://stockhub.co/research/Iovance_Biotherapeutics,_Inc."